Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label bms-790052-declatasvir. Show all posts
Showing posts with label bms-790052-declatasvir. Show all posts
Wednesday, May 15, 2013

Hepatitis C Therapy Update 2013-What About Interferon-free Regimens?

›
Current Opinion in Gastroenterology Hepatitis C Virus Therapy Update 2013 Lisa C. Casey, William M. Lee Curr Opin Gastroenterol. 2013;29(3...
Tuesday, April 30, 2013

Cost will limit uptake of off-label Gilead/Bristol-Myers Squibb Hep C combo, despite best-in-class data

›
ViewPoints: Cost will limit uptake of off-label Gilead/Bristol-Myers Squibb Hep C combo, despite best-in-class data   Ref: ViewPoints Des...
Sunday, April 28, 2013

Hepatitis C - Will physicians go off label, and prescribe Sofosbuvir and Daclatasvir?

›
Hello folks, In short, as most of you know Daclatasvir is a Bristol-Myers-Squibb drug - Sofosbuvir is Gilead's drug. The controversy be...
Thursday, April 11, 2013

Review: NS5A Inhibitors in the Treatment of Hepatitis

›
Accepted Manuscript Review NS5A Inhibitors in the Treatment of Hepatitis C Jean-Michel Pawlotsky PII: S0168-8278(13)00209-2 DOI: http://...

Treatment of hepatitis C virus infection in the future

›
Review- View Full Text Here Treatment of hepatitis C virus infection in the future Tatsuo Kanda, Osamu Yokosuka and Masao Omata Clinical a...
Wednesday, February 20, 2013

Daclatasvir-Computer modeling reveals how surprisingly potent the hepatitis C drug is

›
LOS ALAMOS, N.M., Feb. 19, 2013—A study by researchers from Los Alamos National Laboratory and a multinational team reveals how daclatasvir,...
Tuesday, December 18, 2012

Daclatasvir: a promising triple therapy for children with chronic hepatitis C

›
Daclatasvir: a promising triple therapy for children with chronic hepatitis C Source - Correspondence Lancet Original Text Anna Alisi a...